npj Breast Cancer
Open Access Publication
Rights and Permissions
Ademuyiwa, F.O., Gao, F., Street, C.R. et al. A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. npj Breast Cancer 8, 134 (2022). https://doi.org/10.1038/s41523-022-00500-3
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Ademuyiwa, Foluso O; Gao, Feng; Street, Cherease R; Chen, Ina; Herndon, John M; Carmody, Madelyn; Davies, Sherri R; Larson, Sarah; Liu, Zheng; Hagemann, Ian S; Gillanders, William E; and et al., "A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013." npj Breast Cancer. 8, 1. 134 (2022).
Supplemental material is available for this article at publisher site.